Dupilumab, marketed as Dupixent, has patent protection that extends to different dates depending on the specific patent and region. While some formulation and method of use patents are set to expire in the coming years, core composition of matter patents are generally understood to have later expiration dates, with some extending into the late 2030s [1].
When do key dupilumab patents expire?
The expiration dates for patents related to dupilumab vary. For instance, a patent titled "Method of treating allergic conditions" is listed with an expiration date in 2037 [2]. Other patents covering aspects like pharmaceutical formulations have earlier expiration dates. DrugPatentWatch.com tracks these patents and their expiration timelines [1].
What is dupilumab used to treat?
Dupilumab is a monoclonal antibody used to treat moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis [3]. It works by inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), key drivers of type 2 inflammation [4].
Can biosimilars be developed before patent expiry?
The development of biosimilars can occur during the patent life of the reference product. However, biosimilar products cannot be approved and marketed until the relevant patents expire or are successfully challenged [1].
How do dupilumab patents compare to other biologics?
Biologic drugs, including monoclonal antibodies like dupilumab, often have complex patent landscapes with multiple patents covering different aspects of the drug. This can lead to longer periods of market exclusivity compared to small molecule drugs. The patent strategies for biologics are designed to protect innovation and investment over extended periods [1].
What is the commercial landscape for dupilumab?
Dupilumab is developed by Sanofi and Regeneron Pharmaceuticals [5]. The drug has achieved significant commercial success due to its efficacy in treating various inflammatory conditions. The patent expirations will be a critical factor in the future competitive landscape, potentially opening the door for biosimilar competition [1, 5].
What is the status of patent litigation for dupilumab?
Patent litigation is common for high-value biologic drugs. Companies often challenge existing patents to pave the way for biosimilar entry or to secure their own market position. Specific details on ongoing or resolved litigation for dupilumab patents can be found through specialized legal and patent tracking resources [1].
What are the potential implications of patent expiry for dupilumab?
Upon patent expiry, the market for dupilumab could open up to biosimilar manufacturers. This typically leads to increased competition, potentially lower drug prices, and wider patient access to treatments [1].
Sources:
[1] DrugPatentWatch.com
[2] https://drugpatentwatch.com/en/drug/dupilumab/patents
[3] Dupixent Prescribing Information. Sanofi.
[4] Wenzel, S. (2017). "What is Dupilumab?". The New England Journal of Medicine, 377(17), 1691-1692.
[5] Sanofi. (2023). Annual Report.